Intelligent Intensive Care Unit (ICU_Delirium)

June 4, 2023 updated by: University of Florida

Motion Analysis of Delirium in Intensive Care Units (ICUs) Subtitle 1: "ADAPT: Autonomous Delirium Monitoring and Adaptive Prevention"

Delirium, as a common complication of hospitalization, poses significant health problems in hospitalized patients. Though about a third of delirium cases can benefit from intervention, detecting and predicting delirium is still very limited in practice. A common characterization of delirium is change in activity level, causing patients to become hyperactive or hypoactive which is manifested in facial expressions and total body movements. This pilot study is designed to test the feasibility of a delirium detection system using movement data obtained from 3-axis wearable accelerometers and commercially available camera with facial recognition video system in conjunction with electronics medical record (EMR) data to analyze the relation of whole-body movement and facial expressions with delirium.

Study Overview

Detailed Description

The aim of the study is to assess the potential of using motion and facial expression data to detect delirium in ICU patients by comparing motion and facial expression patterns in delirium and control groups. In this study, the investigators will use ActiGraph accelerometers to record each subject's movement patterns. Also, a processed video using a commercially available camera interfaces with a specialized program to identify patient facial expressions and movement patterns. A total of 60 participants will be enrolled with delirium, and 30 patients without delirium will be used as control group. Motion profiles will be compared in the motorically defined subgroups (hyperactive, hypoactive, normal) based on accelerometer and facial recognition data. Then, differences in facial expression, number of changes in postures, and percentage of time spent moving will be compared between motorically defined subgroups and in delirium and control groups. EMR data will also be used to assess the feasibility of detecting delirium by including additional information on related risk factors.

Study Type

Observational

Enrollment (Estimated)

130

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Florida
      • Gainesville, Florida, United States, 32610
        • UF Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

ICU Patients: Patients who been hospitalized in an intensive care unit and have risk factors to develop delirium or delirium has been suspected by their medical provider.

Healthy Controls: People who are healthy and sleep in their home environment.

Description

Inclusion Criteria (ICU Patients):

  • Intensive care unit patient
  • 18 years of age or older

Exclusion Criteria (ICU Patients):

  • Anticipated intensive care unit stay less than one day
  • Less than 18 years of age
  • Inability to wear a motion sensor watch (ActiGraph)

Inclusion Criteria (Healthy Controls):

  • 18 years of age or older.
  • sleeps in home environment

Exclusion Criteria (Healthy Controls):

  • does not sleep in home environment
  • Less than 18 years of age
  • Inability to wear a motion sensor watch (ActiGraph)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Delirium group
ICU patients with a positive Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
Confusion Assessment Method (CAM) score
3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor
As part of facial recognition video system
Other Names:
  • imaging
Monitors noise levels in the room
Other Names:
  • Sound detection
Control group
ICU patients with a negative Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
Confusion Assessment Method (CAM) score
3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor
As part of facial recognition video system
Other Names:
  • imaging
Monitors noise levels in the room
Other Names:
  • Sound detection
Healthy control group
Healthy subjects that sleep in their home environment; observational using accelerometers, cortisol swabs, and Internet Pod (iPod)
3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor
Monitors noise levels in the room
Other Names:
  • Sound detection
Cortisol level collected through self administered salivary swab

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
CAM/CAM-ICU
Time Frame: Changes from Baseline up to 7 Days
Confusion Assessment Method for detection of delirium
Changes from Baseline up to 7 Days
Memorial Delirium Assessment Scale (MDAS) will be used for changes from baseline up to 7 days between the groups.
Time Frame: Changes from Baseline up to 7 Days
MDAS denotes motor profile and defines motor subtyping. It has 10 items which assesses several areas of cognitive functioning (memory, attention, orientation and disturbances in thinking) and psychomotor activity. The items are rated on a four point scale (0-3) based on the current interaction with the patient or by assessment of behavior. A score of 13 shows the diagnosis of delirium.
Changes from Baseline up to 7 Days
Delirium Motor Subtyping Scale (DMSS-4) will be used for changes from baseline up to 7 days between the groups.
Time Frame: Changes from Baseline up to 7 Days
Scoring from DMSS-4 which has 5 hyperactive and 8 hypoactive symptoms requires at least two symptoms to be present from either the hyperactive or hypoactive list to meet subtype criteria. The higher the score the higher the delirium.
Changes from Baseline up to 7 Days
Freedman Sleep Scale
Time Frame: Changes from Baseline up to 7 Days
To determine sleep quality of patient for given day.
Changes from Baseline up to 7 Days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of subjects who died
Time Frame: Baseline up to 7 Days
Death at any time during admission
Baseline up to 7 Days
Number of subjects on mechanical ventilation
Time Frame: greater than 48 hours
Number of subjects requiring mechanical ventilation greater than 48 hours.
greater than 48 hours

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Facial amimia versus non-amimia expressions between the groups
Time Frame: Changes from Baseline up to 7 Days
Frequency of presence of facial amimia versus non-amimia expressions between the groups.
Changes from Baseline up to 7 Days
Dynamic activity versus static position
Time Frame: Changes from Baseline up to 7 Days
Percentage of time spent moving versus static position
Changes from Baseline up to 7 Days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2016

Primary Completion (Actual)

March 11, 2020

Study Completion (Estimated)

May 30, 2025

Study Registration Dates

First Submitted

May 29, 2015

First Submitted That Met QC Criteria

June 3, 2015

First Posted (Estimated)

June 8, 2015

Study Record Updates

Last Update Posted (Actual)

June 6, 2023

Last Update Submitted That Met QC Criteria

June 4, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • IRB201400546 -N
  • 1750192 (Other Grant/Funding Number: National Science Foundation)
  • 1R21EB027344-01 (U.S. NIH Grant/Contract)
  • R01NS120924-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delirium

Clinical Trials on Confusion Assessment Method

3
Subscribe